NCT06509022

Brief Summary

The goal of this observational study intends to explore the evolution trend and related factors of postoperative reflux of esophageal cancer based on PEPTEST detection, in order to identify postoperative reflux The main question it aims to answer are: to provide evidence for high-risk groups, improvement of surgical methods for esophageal cancer, and development of health education programs to prevent postoperative reflux. Using convenient sampling method, patients undergoing esophagectomy in thoracic surgery Department of Cancer Hospital of Chinese Academy of Medical Sciences from January 1, 2023 were continuously enrolled. PEPTEST was performed once before surgery, before discharge, 1 month, 3 months, and 6 months after surgery. The incidence of pathological reflux at 5 time points before and after surgery was observed and compared (that is, both T-line and C-line were shown). The trend of pepsin content in saliva before and after operation; The relationship between pathological reflux and surgical factors; The relationship between pathological reflux and life habits after operation; Relationship between pathological regurgitation and demographic characteristics.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
138

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Mar 2024

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

August 26, 2023

Completed
6 months until next milestone

Study Start

First participant enrolled

March 1, 2024

Completed
5 months until next milestone

First Posted

Study publicly available on registry

July 19, 2024

Completed
5 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2024

Completed
Last Updated

July 19, 2024

Status Verified

March 1, 2024

Enrollment Period

9 months

First QC Date

August 26, 2023

Last Update Submit

July 12, 2024

Conditions

Outcome Measures

Primary Outcomes (1)

  • Incidence of pathological regurgitation

    Incidence of pathological regurgitation at 5 time points before and after surgery.

    2023.1.1-2023.12.1

Study Arms (5)

Before surgery

A patient with esophageal cancer before surgery

Diagnostic Test: PEPTEST test

Before discharge

Patients with esophageal cancer who were not discharged after surgery

Diagnostic Test: PEPTEST test

1 month after surgery

One month after surgery for esophageal cancer

Diagnostic Test: PEPTEST test

3 months after surgery

Three months after surgery for esophageal cancer

Diagnostic Test: PEPTEST test

6 months after surgery

Six months after surgery for esophageal cancer

Diagnostic Test: PEPTEST test

Interventions

PEPTEST testDIAGNOSTIC_TEST

Quantitative determination of gastric salivary amylase。

1 month after surgery3 months after surgery6 months after surgeryBefore dischargeBefore surgery

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients who underwent resection for esophageal cancer were continuously enrolled.

You may qualify if:

  • Patients who were pathologically diagnosed with esophageal cancer and underwent esophagectomy for esophageal cancer.
  • The patient can communicate in Mandarin.
  • Those who can come to the hospital for review on time.

You may not qualify if:

  • People with cognitive impairment or mental illness.
  • Complicating other serious life-threatening diseases (such as leukemia or autoimmune diseases).
  • Unwilling to participate in the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Beijing, China

Location

MeSH Terms

Conditions

Gastrointestinal Neoplasms

Condition Hierarchy (Ancestors)

Digestive System NeoplasmsNeoplasms by SiteNeoplasmsDigestive System DiseasesGastrointestinal Diseases

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
CROSS SECTIONAL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 26, 2023

First Posted

July 19, 2024

Study Start

March 1, 2024

Primary Completion

December 1, 2024

Study Completion

December 1, 2024

Last Updated

July 19, 2024

Record last verified: 2024-03

Data Sharing

IPD Sharing
Will not share

Locations